Dr Charlie Massie

University of Cambridge
Cancer Research UK Cambridge Institute
Department of Oncology
CRUK Cambridge Institute
Hutchison MRC Research Centre
Early Detection Programme, Urological Malignacies Programme

Position: Group Leader
Personal home page: http://www.molecularinformatics.org

PubMed journal articles - click here

Dr Charlie Massie is pleased to consider applications from prospective PhD students.

Research description

Integrating cancer genomics, epigenetics, bioinformatics and circulating tumour DNA analysis. Working together with collaborators to provide insights into disease biology and to build clinically useful tests.

Research Programme
Urological Malignancies
Methods and technologies
Bioinformatics
Cell culture
Confocal microscopy
DNA sequencing
Fluorescence microscopy
Gene expression profiling
Genomics
Immunohistochemistry
Metabolomics
Microarray
PCR
Protein biochemistry
Protein purification
Proteomics
Recombinant protein expression
RNAi
Statistical analysis
Tumour type interests
Bladder
Brain and central nervous system
Breast
Colorectal
Kidney
Leukemia
Liver
Lung
Melanoma
Oesophagus
Prostate
Keywords
Cancer
genomics
transcription factor
epigenetics
DNA methylation
androgen receptor
prostate cancer
bioinformatics
ctDNA.
cem45
Recent publications:
 Retrieving latest data from feed...

Symplectic Elements feed provided by Research Information, University of Cambridge


Key publications

Massie CE, Mills IG, Lynch AG. The importance of DNA methylation in prostate cancer development. JSBMB 2016 pii:S0960-0760(16)30105-4.

Cooper CS, et al; ICGC Prostate Group. Analysis of the genetic phylogeny of multifocal prostate cancer identifies multiple independent clonal expansions in neoplastic and morphologically normal prostate tissue. Nat Genet. 2015;47(4):367-72.

Massie CE, et al; UK Prostate ICGC Group. HES5 silencing is an early and recurrent change in prostate tumourigenesis. ERC 2015;22(2):131-44.

Pertega-Gomes N, ..., Massie CE. Epigenetic and oncogenic regulation of SLC16A7 (MCT2) results in protein over-expression, impacting on signalling and
cellular phenotypes in prostate cancer. Oncotarget. 2015;6(25):21675-84.

Asim M, Massie CE, et al. Choline Kinase Alpha as an Androgen Receptor Chaperone and Prostate Cancer Therapeutic Target. JNCI 2015;108(5).

Chen E, Ahn JS, Massie CE, et al. JAK2V617F promotes replication fork stalling with disease-restricted impairment of the intra-S checkpoint response. PNAS 2014;111(42):15190-5.

Nangalia J, Massie CE, et al. Somatic CALR mutations in myeloproliferative neoplasms with nonmutated JAK2. NEJM 2013;369(25):2391-405

Sharma NL, Massie CE, et al. The androgen receptor induces a distinct transcriptional program in castration-resistant prostate cancer in man. Cancer Cell. 2013;23(1):35-47

Massie CE, et al. The androgen receptor fuels prostate cancer by regulating central metabolism and biosynthesis. EMBO J. 2011;30(13):2719-33.